New York State Common Retirement Fund Sells 364,567 Shares of Kenvue Inc. (NYSE:KVUE)

New York State Common Retirement Fund decreased its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 13.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,447,176 shares of the company's stock after selling 364,567 shares during the quarter. New York State Common Retirement Fund owned 0.13% of Kenvue worth $58,683,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Clarity Asset Management Inc. bought a new position in shares of Kenvue during the 4th quarter valued at approximately $45,000. Continuum Advisory LLC increased its position in shares of Kenvue by 2,071.1% during the 1st quarter. Continuum Advisory LLC now owns 1,954 shares of the company's stock valued at $47,000 after purchasing an additional 1,864 shares during the last quarter. Rossby Financial LCC bought a new position in shares of Kenvue during the 1st quarter valued at approximately $52,000. Golden State Wealth Management LLC increased its position in shares of Kenvue by 292.0% during the 1st quarter. Golden State Wealth Management LLC now owns 3,081 shares of the company's stock valued at $74,000 after purchasing an additional 2,295 shares during the last quarter. Finally, Versant Capital Management Inc increased its position in shares of Kenvue by 77.9% during the 1st quarter. Versant Capital Management Inc now owns 3,415 shares of the company's stock valued at $82,000 after purchasing an additional 1,495 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Kenvue Price Performance

Shares of KVUE stock opened at $21.35 on Monday. Kenvue Inc. has a twelve month low of $17.85 and a twelve month high of $25.17. The stock has a market capitalization of $40.96 billion, a price-to-earnings ratio of 38.82, a P/E/G ratio of 3.32 and a beta of 0.83. The stock has a fifty day simple moving average of $22.34 and a two-hundred day simple moving average of $22.29. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63.

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.01. The business had revenue of $3.74 billion during the quarter, compared to analysts' expectations of $3.69 billion. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The business's revenue for the quarter was down 3.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.28 EPS. On average, analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.84%. The ex-dividend date of this dividend was Wednesday, May 14th. Kenvue's dividend payout ratio (DPR) is currently 149.09%.

Analysts Set New Price Targets

KVUE has been the topic of several analyst reports. UBS Group boosted their target price on Kenvue from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Friday, May 9th. Redburn Atlantic began coverage on Kenvue in a report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price objective for the company. Citigroup restated a "neutral" rating on shares of Kenvue in a report on Friday, June 13th. Barclays boosted their price objective on Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a report on Monday, May 12th. Finally, Evercore ISI began coverage on Kenvue in a report on Monday, March 24th. They set an "in-line" rating and a $25.00 price objective for the company. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $25.33.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.